Home > Back to Publisher > Report Information
|
|
| Countries covered: Global This report analyzes the worldwide markets for Asthma Therapeutics in US$ Million. The major therapeutic segments analyzed are Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, and Anti- leukotrienes. The report provides separate comprehensive analytics for the USA, Canada, Japan, Europe and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2010. The report profiles 70 companies including many key and niche players worldwide such as Abbott Laboratories, ALTANA Pharma AG, AstraZeneca, Boehringer Ingelheim, Genentech, Inc., GlaxoSmithKline, Merck & Co., Inc., Novartis Pharma AG, Pfizer Inc., Schering-Plough Corporation and 3M. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources. Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location. Adobe Acrobat Reader 7.0 is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report. Titles available via "online download" are not affected by this and are still delivered to your personal library immediately. Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. |
- I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
- Study Reliability And Reporting Limitations
- Disclaimers
- Data Interpretation & Reporting Level
- Quantitative Techniques & Analytics
- Product Definitions And Scope Of Study
- Inhaled Corticosteroids:
- Beta-2 Adrenoreceptor Agonists
- Combinations
- Anti- leukotrienes
- Others
- Antihistamines
- Methylxanthines
- Mast Cell Stabilizers
- Monoclonal Antibodies
- Anticholinergics
- II. EXECUTIVE SUMMARY
- 1. Market Overview
- Current & Future Analysis
- Competitive Outlook
- Major Asthma Therapeutics by Class
- Facts about Asthma
- 2. Trends & Issues
- Combination Drugs - Rule the World
- Novel Compounds To Pep Up Growth
- Rise in Pediatric Asthma To Keep Market Lucrative
- Toxic Nature of Asthma Drugs - A Serious Concern
- Life Threatening Drugs Under Regulatory Scan
- 3. Product Overview
- Causes of Asthma
- Allergens
- Irritants
- Other Factors
- Classes in Asthma
- A. Mild Intermittent Asthma:
- B. Mild Persistent Asthma:
- C. Moderate Persistent Asthma:
- D. Severe Persistent Asthma:
- Asthma Treatments
- Combination Asthma Medications
- Over-the-Counter Asthma Medications
- Immunotherapy (Allergy shots)
- Alternative Therapies
- Asthma Therapeutics
- Corticosteroids
- Beta-2 Adrenoreceptor Agonists
- Mast Cell Stabilizers
- Monoclonal Antibodies
- Immune System: Natural Defenders
- Human Antibodies
- Polyclonal and Monoclonal Antibodies
- Leukotriene Inhibitors
- Methylxanthines:
- Combination Therapeutics:
- Off Label Therapeutics:
- Anticholinergics:
- Antihistamines:
- Asthma Therapeutics by Various Classes
- 4. Product Launches/Innovations
- Future to Witness A Novel Therapeutic in Asthma Treatment
- Dr. Reddy’s Releases Doxobid in India
- Novartis Files Approval for Xolair to Enter Japanese Market
- AstraZeneca Receives Approval for Symbicort
- GSK Alters Labels for Two Asthma Drugs
- DMI BioSciences Starts Evaluating DMI 8393
- Inflazyme Begins Phase IIb Trial for IPL512,602
- Neurim Develops A Neuroprotective Compound
- Xolair® Forays into UK
- Critical Therapeutics Rolls Out ZYFLO®
- Ivax Corp. Introduces Qvar EasiBreathe Inhaler
- Altana Rolls Out Respiratory Drug, Alvesco in the UK
- Sepracor Launches XOPENEX HFA
- Polyphor Commences Research for Protease Inhibitors
- Novartis Plans to Apply for A New Drug Approval
- Asmanex Twisthaler 220 mcg Receives US FDA Approval
- GroPep Completes Pre-Clinical Testing of T-Cell Peptide Drug
- Able Laboratories Obtains FDA Approval
- Acceleration Therapeutics’ AT-101 Passes Laboratory Test
- Pharmaxis’ New Tool to Assess Asthma Passes Clinical Trial
- Aventis Seeks FDA Approval Alvesco®
- Schering-Plough Releases Asmanex Twisthaler
- FDA Clears Xolair to Enter US Market
- Sepracor Completes Phase III Trial for XOPENEX
- Pfizer Conducts Phase II Clinical Studies
- Celera and Bayer Plans to End Collaboration
- Banyu and Kyorin Starts Distribution of Asthma Treatment
- GlaxoSmithKline Introduces Advair
- Novartis Gets FDA Approval for Foradil Aerolizer
- 5. Recent Industry Activity
- Teva Purchases Ivax
- SkyePharma Strikes A Deal with KOSP
- Ranbaxy Inks an In-Licensing Agreement with Eurodrug
- Pfizer and Rigel Forms A Collaboration
- MAP and Elan Extends Agreement
- Glenmark Collaborates with Teijin Pharma
- Pfizer Acquires Meridica
- Bayer and Apax Forms A New Company
- KOSP Signs Multiple Agreements
- Novartis Pharma Inks A Licensing Agreement with Ivax
- LAB Intends to Purchase Seyvika
- ALTANA and Tanabe Signs A Pact
- 6. Focus on Select Players
- Abbott Laboratories (US)
- ALTANA Pharma AG (Germany)
- AstraZeneca (UK)
- Boehringer Ingelheim (Germany)
- Genentech, Inc. (US)
- GlaxoSmithKline (UK)
- Merck & Co., Inc. (US)
- Novartis Pharma AG (Switzerland)
- Pfizer Inc. (US)
- Schering-Plough Corporation (US)
- Sepracor Inc. (US)
- The Sanofi-Aventis Group (US)
- 3M (US)
- 7. Global Market Perspective
- Table 1: World Recent Past, Current and Future Analysis for Asthma Therapeutics by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
- Table 2: World 10-Year Perspective for Asthma Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart)
- Table 3: World Recent Past, Current and Future Analysis for Inhaled Corticosteroids by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
- Table 4: World 10-Year Perspective for Inhaled Corticosteroids by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart)
- Table 5: World Recent Past, Current and Future Analysis for Short Acting Beta Agonists by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
- Table 6: World 10-Year Perspective for Short Acting Beta Agonists by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart)
- Table 7: World Recent Past, Current and Future Analysis for Long Acting Beta Agonists by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
- Table 8: World 10-Year Perspective for Long Acting Beta Agonists by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart)
- Table 9: World Recent Past, Current and Future Analysis for Combinations by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
- Table 10: World 10-Year Perspective for Combinations by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart)
- Table 11: World Recent Past, Current and Future Analysis for Anti-Leukotrienes by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
- Table 12: World 10-Year Perspective for Anti-Leukotrienes by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart)
- Table 13: World Recent Past, Current and Future Analysis for Other Asthma Therapeutics by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
- Table 14: World 10-Year Perspective for Other Asthma Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart)
- III. MARKET
- 1. The United States
- A.Market Analysis
- Current & Future Analysis
- Asthma Reflections in the US
- Competitive Scenario
- Table 15: Leading Anticholinergic Companies in the US (2006): Percentage Breakdown of Market Share for Boehringer Ingelheim, Dey Inc, Alpharma and Others (includes corresponding Graph/Chart)
- Product Launches/Innovations
- Strategic Developments
- Focus on Key Players
- 3M
- Abbott Laboratories
- Genentech, Inc.
- Merck & Co., Inc.
- Pfizer Inc.
- Schering-Plough Corporation
- Sepracor Inc.
- The Sanofi-Aventis Group
- B.Market Analytics
- Table 16: US Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment - Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
- Table 17: US 10-Year Perspective for Asthma Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart)
- 2. Canada
- A.Market Analysis
- Current & Future Analysis
- Product Launches/Innovations
- Strategic Development
- B.Market Analytics
- Table 18: Canadian Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment - Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
- Table 19: Canadian 10-Year Perspective for Asthma Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart)
- 3. Japan
- A.Market Analysis
- Current & Future Analysis
- Product Approvals/Launches
- Strategic Developments
- B.Market Analytics
- Table 20: Japanese Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment - Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets IndependentlyAnalyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
- Table 21: Japanese 10-Year Perspective for Asthma Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart)
- 4. Europe
- Market Analysis
- Current & Future Analysis
- Table 22: European Recent Past, Current and Future Analysis for Asthma Therapeutics by Geographic Region - France, Germany, UK, Italy, Spain and Rest of Europe Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
- Table 23: European Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment - Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
- Table 24: European 10-Year Perspective for Asthma Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, UK, Italy, Spain and Rest of Europe for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart)
- Table 25: European 10-Year Perspective for Asthma Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart)
- 4a. France
- Market Analysis
- Current & Future Analysis
- Table 26: French Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment - Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
- Table 27: French 10-Year Perspective for Asthma Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart)
- 4b. Germany
- A.Market Analysis
- Current & Future Analysis
- Product Launches/Innovations
- Focus on Key Players
- ALTANA Pharma AG
- Boehringer Ingelheim
- B.Market Analytics
- Table 28: German Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment - Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
- Table 29: German 10-Year Perspective for Asthma Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart)
- 4c. The United Kingdom
- A.Market Analysis
- Current & Future Analysis
- Product Launches/Innovations
- Strategic Developments
- Focus on Key Players
- AstraZeneca
- GlaxoSmithKline
- B.Market Analytics
- Table 30: UK Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment - Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
- Table 31: UK 10-Year Perspective for Asthma Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart)
- 4d. Italy
- Market Analysis
- Current & Future Analysis
- Table 32: Italian Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment - Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
- Table 33: Italian 10-Year Perspective for Asthma Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart)
- 4e. Spain
- Market Analysis
- Current & Future Analysis
- Table 34: Spanish Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment - Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
- Table 35: Spanish 10-Year Perspective for Asthma Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart)
- 4f. Rest of Europe
- A.Market Analysis
- Current & Future Analysis
- Product Approvals/Launches
- Strategic Development
- Focus on Select Player
- Novartis Pharma AG (Switzerland)
- B.Market Analytics
- Table 36: Rest of Europe Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment - Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
- Table 37: Rest of Europe 10-Year Perspective for Asthma Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart)
- 5. Rest of World
- A.Market Analysis
- Current & Future Analysis
- Product Launches
- Strategic Developments
- B.Market Analytics
- Table 38: Rest of World Recent Past, Current and Future Analysis for Asthma Therapeutics by Product Segment - Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
- Table 39: Rest of World 10-Year Perspective for Asthma Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, Anti- leukotrienes and Other Asthma Therapeutics Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart)
- IV. COMPETITION
- 1. 3M Company (USA)
- Table 40: First Quarter Sales Analysis: 2005-2006 (In US$ billion)
- Table 41: First Quarter Sales Analysis by Segment: 2005-2006 (In US$ billion)
- Table 42: Annual Sales Analysis: 2004-2005 (In US$ billion)
- Table 43: Annual Sales Analysis by Segment: 2004-2005 (In US$ billion)
- Table 44: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ billion)
- 2. Abbott Laboratories (USA)
- 3. Able Laboratories, Inc. (USA)
- 4. Adams Respiratory Therapeutics (USA)
- Table 45: Annual Sales Analysis: 2004-2006 (In US$ million)
- Table 46: Annual Sales Analysis by Quarter: 2005-2006 (In US$ million)
- Table 47: Annual Sales Analysis by Product: 2005-2006 (In US$ million)
- Table 48: Annual Sales Analysis by Product: 2004-2005 (In US$ million)
- 5. Aerovance, Inc. (USA)
- 6. Almirall Prodesfarma SA (Spain)
- 7. Alpharma USPD, Inc. (USA)
- 8. Altana Pharma AG (Germany)
- Table 49: Annual Sales Analysis: 2004-2005 (In € billion)
- Table 50: Annual Sales Analysis by Product Segment: 2004-2005 (In € billion)
- Table 51: Annual Sales Analysis by Geographical Region: 2004-2005 (In € billion)
- 9. Amgen, Inc. (USA)
- Table 52: First Quarter Sales Analysis: 2005-2006 (In US$ million)
- Table 53: Annual Sales Analysis: 2004-2005 (In US$ million)
- Table 54: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
- 10. Asthmatx, Inc. (USA)
- 11. Astrazeneca PLC (UK)
- Table 55: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ Million)
- Table 56: Half Yearly Sales Analysis By Quarter: 2005- 2006 (H1) (In US$ Million)
- Table 57: Half Yearly Sales Analysis By Geographic Region: 2005-2006 (H1) (In US$ Million)
- Table 58: Annual Sales Analysis By Quarter: 2004-2005 (In US$ Million)
- Table 59: Annual Sales Analysis By Geographic Region: 2004-2005 (In US$ Million)
- Astrazeneca Pharmaceuticals LP (USA)
- 12. Biocon India Limited (India)
- Table 60: Annual Sales Analysis: 2004-2005 (In INR million)
- 13. Boehringer Ingelheim GmbH (Germany)
- Boehringer Ingelheim Pharmaceuticals, Inc. (USA)
- Boehringer Ingelheim Ltd. (Canada)
- 14. Breckenridge Pharmaceutical, Inc. (USA)
- 15. Cadila Pharmaceuticals Limited (India)
- 16. Cipla Ltd. (India)
- 17. Coley Pharmaceutical Group, Inc. (USA)
- Table 61: Half-Yearly Sales Analysis: 2006-2005 (H1) (In Can$ thousands)
- Table 62: Quarterly Sales Analysis: 2005-2004 (In Can$ thousands)
- 18. Cosmobio Co., Ltd. (Japan)
- 19. Critical Therapeutics, Inc. (USA)
- Table 63: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
- 20. deCODE Genetics (Iceland)
- Table 64: First Quarter Sales Analysis: 2005-2006 (In US$ million)
- Table 65: Annual Sales Analysis: 2004-2005 (In US$ million)
- Table 66: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
- Table 67: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
- 21. DMI BioSciences, Inc. (USA)
- 22. Dr. Reddy's Laboratories (India)
- Table 68: First Quarter Sales Analysis: 2005-2006 (Q1) (In INR billion)
- Table 69: Annual Sales Analysis: 2004-2005 (In INR billion)
- Table 70: Annual Sales Analysis by Segment: 2004-2005 (In INR billion)
- Table 71: Annual Sales Analysis by Geographic Region: 2004-2005 (In INR billion)
- 23. Elan Corporation Plc (Ireland)
- Table 72: First Quarter Sales Analysis: 2005-2006 (In US$ million)
- Table 73: Annual Sales Analysis: 2004-2005 (In US$ million)
- Table 74: Annual Sales Analysis By Segment: 2004-2005 (In US$ million)
- Table 75: Annual Sales Analysis By Geographic Region: 2004-2005 (In US$ million)
- 24. Epitomics, Inc. (USA)
- 25. Eurodrug Laboratories Group (The Netherlands)
- 26. Exim Pharm International (India)
- 27. F. Hoffmann-La Roche Ltd. (Switzerland)
- Table 76: First Quarter Sales Analysis: 2005-2006 (In CHF billion)
- Table 77: First Quarter Sales Analysis by Segment: 2005-2006 (In CHF billion)
- Hoffmann-La Roche, Inc. (USA)
- Genentech, Inc. (USA)
- Table 78: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
- Table 79: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) (Switzerland))
- 28. Forest Laboratories, Inc. (USA)
- Table 80: First Quarter Sales Analysis: 2006-2007 (In US$ billion)
- Table 81: Annual Sales Analysis: 2004-2006 (In US$ billion)
- Table 82: Annual Sales Analysis by Product: 2005-2006 (In US$ billion)
- Table 83: Annual Sales Analysis by Geographic Region: 2005-2006 (In US$ billion)
- Table 84: Quarterly Sales Analysis: 2005-2006 (In US$ billion)
- 29. Gilead Sciences (USA)
- Table 85: Half Yearly Sales Analysis by Quarter: 2005- 2006 (H1) (In USS$ million)
- Table 86: Half Yearly Sales Analysis by Geographic Region: 2005-2006 (H1) (In USS$ million)
- Table 87: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
- Table 88: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
- 30. Glaxosmithkline PLC (UK)
- Table 89: Half Yearly Sales Analysis: 2005-2006 (H1) (In £ million)
- Table 90: Half Yearly Sales Analysis by Segment: 2005- 2006 (H1) (In £ million)
- Table 91: Annual Sales Analysis by Segment: 2004-2005 (In £ million)
- Glaxosmithkline (USA)
- 31. Glenmark Pharmaceuticals Ltd. (India)
- Glenmark Pharmaceuticals SA (Switzerland)
- 32. GroPep Limited (Australia)
- Table 92: Annual Sales Analysis by Business Segment: 2005-2006 (In A$ million)
- 33. Indoco Remedies (India)
- 34. Inflazyme Pharmaceuticals Limited (Canada)
- 35. Janssen-Cilag GmbH (Austria)
- 36. Kos Pharmaceuticals, Inc. (USA)
- Table 93: First Quarter Sales Analysis: 2005-2006 (In US$ million)
- Table 94: Annual Sales Analysis: 2004-2005 (In US$ million)
- 37. Kyorin Pharmaceutical Co., Ltd. (Japan)
- 38. Lab International, Inc. (Canada)
- Table 95: Annual Sales Analysis by Business Segment: 2004-2005 (In Can$ million)
- Table 96: Annual Sales Analysis by Geographic Region: 2004-2005 (In Can$ million)
- 39. Lark Laboratories (India)
- 40. MAP Pharmaceuticals, Inc. (USA)
- 41. Mayne Pharma Pty, Ltd. (Australia)
- Table 97: Annual Sales Analysis By Segment: 2004-2005 (In A$ Million)
- Table 98: Annual Sales Analysis By Geographic Region: 2004-2005 (In A$ Million)
- 42. MediciNova, Inc. (USA)
- Table 99: Half-Yearly Sales Analysis: 2005-2006 (H1) (In US$ Thousand)
- 43. Mercia Pharma, Inc. (USA)
- 44. Merck KGaA (Germany)
- Table 100: Annual Sales Analysis Segment: 2004-2005 (In € million)
- Merck & Co., Inc. (USA)
- Table 101: Half Yearly Sales Analysis By Quarter: 2005 -2006 (H1) (In US$ million)
- Table 102: Half Yearly Sales Analysis by Product: 2005 -2006 (H1) (In US$ million)
- Table 103: Annual Sales Analysis by Product: 2004-2005 (In US$ million)
- Table 104: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
- Banyu Pharmaceutical Co., Ltd. (Japan)
- Dey, L.P. (USA)
- 45. Millennium Pharmaceuticals, Inc. (USA)
- Table 105: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
- Table 106: Quarterly Sales Analysis: 2004-2005 (In US$ million)
- 46. MorphoSys AG (Germany)
- Table 107: First Quarter Sales Analysis: 2005-2006 (Q1) (In € million)
- 47. Neurim Pharmaceuticals (1991) Ltd. (Israel)
- 48. Nicholas Piramal India Ltd. (India)
- Table 108: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ million)
- 49. Novartis AG (Switzerland)
- Table 109: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
- Table 110: Half Yearly Sales Analysis by Segment: 2005 -2006 (H1) (In US$ million)
- Table 111: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)
- Table 112: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
- Novartis Pharma Switzerland AG (Switzerland)
- Novartis Pharma GmbH (Germany)
- Sandoz International GmbH (Germany)
- 50. Oriel Therapeutics, Inc. (USA)
- 51. Pfizer, Inc. (USA)
- Table 113: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ billion)
- Table 114: Half Yearly Sales Analysis by Segment: 2005 -2006 (H1) (In US$ billion)
- Table 115: Half Yearly Sales Analysis by Geographic Region: 2005-2006 (H1) (In US$ billion)
- Pfizer Consumer Healthcare Division (USA)
- 52. Pharmaxis Ltd. (Australia)
- 53. Polyphor Limited (Switzerland)
- 54. Pure Pharma Limited (India)
- 55. Ranbaxy Laboratories Ltd. (India)
- 56. Rigel Pharmaceuticals, Inc. (USA)
- Table 116: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
- Table 117: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
- 57. Sanofi-Aventis (France)
- Table 118: Half Yearly Sales Analysis: 2005-2006 (H1) (In € million)
- Table 119: Half Yearly Sales Analysis by Quarter: 2005 -2006 (H1) (In € million)
- Table 120: Annual Sales Analysis: 2004-2005 (In € million)
- Table 121: Annual Sales Analysis by Segment: 2004-2005 (In € million)
- Table 122: Annual Sales Analysis by Geographic Region: 2004-2005 (In € million)
- Sanofi-Aventis (USA)
- 58. Schering-Plough Corporation (USA)
- Table 123: Half Yearly Sales Analysis by Segment: 2005 -2006 (H1) (In US$ million)
- Table 124: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)
- Table 125: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
- Table 126: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
- AESCA Pharma GmbH (Austria)
- 59. Sepracor, Inc. (USA)
- Table 127: Half Yearly Sales Analysis by Quarter: 2005 -2006 (H1) (In US$ million)
- Table 128: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
- 60. Shinpoong Pharmaceutical Co., Ltd. (South Korea)
- 61. SkyePharma PLC (UK)
- Table 129: Half Yearly Sales Analysis by Segment: 2005 -2006 (H1) (In £ million)
- Table 130: Annual Sales Analysis by Segment: 2004-2005 (In £ million)
- Table 131: Annual Sales Analysis by Geographic Region: 2004-2005 (In £ million)
- 62. Sumit Laboratories (India)
- 63. Surya Pharmaceutical Ltd. (India)
- 64. Synairgen Research Limited (UK)
- 65. Tanabe Seiyaku Co., Ltd. (Japan)
- Table 132: First Quarter Sales Analysis: 2006-2007 (Q1) (In US$ million)
- Table 133: First Quarter Sales Analysis by Business Segment: 2005-2006 (Q1) (In Yen million)
- Table 134: Annual Sales Analysis: 2005-2006 (In US$ million)
- Table 135: Annual Sales Analysis by Business Segment: 2004-2005 (In Yen million)
- 66. TEVA Pharmaceutical Industries Ltd. (Israel)
- Table 136: Half Yearly Sales Analysis by Quarter: 2005 -2006 (H1) (In US$ million)
- Table 137: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
- IVAX Corporation (USA)
- Table 138: Nine Months Sales Analysis: 2004-2005 (Nine Months Ended, September) (In US$ billion)
- Table 139: Quarterly Sales Analysis: 2004-2005 (Nine Months Ended, September) (In US$ billion)
- Table 140: Nine Months Sales Analysis by Product Category: 2004-2005 (Nine Months Ended, September) (In US$ billion)
- Table 141: Nine Months Sales Analysis by Geographical Region: 2004-2005 (Nine Months Ended, September) (In US$ billion)Limited (Israel))
- Ivax Laboratories, Inc. (USA)
- 67. Trudell Medical International (Canada)
- 68. UCB SA (Belgium)
- Table 142: Annual Sales Analysis: 2004-2005 (In € million)
- Table 143: Annual Sales Analysis By Business Segment: 2004-2005 (In € million)
- 69. Zedawn Formulations (P) Ltd. (India)
- 70. Zenyth Therapeutics Limited (Australia)
- Table 144: Annual Sales Analysis: 2004-2005 (In A$ million)
More Global Allergy/Immunology Reports
The World Market for Over The Counter (OTC) Drugs by
Kalorama Information
Over-the-counter (OTC), non-legend, and non-prescription are all adjectives describing drugs that an individual may purchase without a prescription. Many pharmaceutical companies seeking more revenue and ...
Nasal Congestion Global Clinical Trials Review, H1, 2012 by
GlobalData
Nasal Congestion Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Nasal Congestion Global Clinical Trials Review, H1, 2012 provides data on the Nasal Congestion ...
Food Allergy and Intolerance Products by
Global Industry Analysts
This report analyzes the worldwide markets for Food Allergy and Intolerance Products in US$ Million by the following product segments: Gluten-free, and Others. The report ...
The 2011-2016 World Outlook for Non-Prescription Decongestants Excluding Nasal Sprays and Nose Drops by
Icon Group International, Inc.
This econometric study covers the world outlook for non-prescription decongestants excluding nasal sprays and nose drops across more than 200 countries. For each year reported, ...
Nicholas Hall's Global Cough, Cold & Allergy Review by
Nicholas Hall and Company
This essential report is the ideal guide to CCA brands and marketers across leading developed and emerging markets, focusing on core trends and exciting developments. ...
See all reports like this >>
Related Markets
- Biotechnology
- Research & Development
- Diseases & Conditions
- Asthma
- Therapeutic Area
- Allergy/Immunology
